SciELO - Scientific Electronic Library Online

 
vol.22 número3Impacto da Cirurgia Bariátrica em Pacientes de Goiás, Brasil, Usando Metodologia BAROS: Um Estudo PreliminarA Importância da Utilização de Exames Complementares Alternativos no Diagnóstico de Tumores do Intestino Delgado Após uma Enteroscopia por Cápsula Negativa índice de autoresíndice de assuntosPesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


GE-Portuguese Journal of Gastroenterology

versão impressa ISSN 2341-4545

Resumo

PALMELA, Carolina; TORRES, Joana  e  CRAVO, Marilia. New Trends in Inflammatory Bowel Disease. GE Port J Gastroenterol [online]. 2015, vol.22, n.3, pp.103-111. ISSN 2341-4545.  https://doi.org/10.1016/j.jpge.2015.03.009.

Inflammatory bowel disease (IBD) is a chronic idiopathic inflammatory disease of the gastrointestinal (GI) tract. In the past decade a shift in the treatment paradigm of IBD has ensued. The availability of drugs capable of inducing mucosal healing, combined with the recognition that IBD is not an intermittent disease, but rather a progressive one causing bowel damage and disability, led us to a more stringent strategy. Tailored therapy with more aggressive treatment in high-risk patients, treating beyond symptoms, intervening early before damage occurs, optimizing therapeutic regimens, and actively pursuing sustained remission and sustained control of inflammation are strategies that are slowly being incorporated in our clinical practice. Furthermore, new drugs targeting different immunological pathways, such a s vedolizumab, have recently been approved and therefore more therapeutic resources for patients failing anti-tumour necrosis factor alpha (anti-TNFa) agents will be available. The future years look promising for IBD. Hopefully the new trends in IBD  management, combined with new drugs, will make possible to change the course of disease and provide better therapy and quality of life for patients suffering from this disabling disease.

Palavras-chave : Antibodies; Monoclonal; Colitis; Ulcerative; Crohn Disease; Inflammatory Bowel Diseases; Molecular Targeted Therapy; Drug Monitoring.

        · resumo em Português     · texto em Inglês     · Inglês ( pdf )

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons